Q-omics provides the consensus-scored HTR1B profile across patient tissues and cancer cell-line models. HTR1B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HTR1B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, HTR1B protein abundance shows 18,821 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where HTR1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR1B survival associations across molecular data types. HTR1B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR1B RNA expression–survival associations across cancer types. High HTR1B expression shows unfavorable associations in MESO, STAD and KIRP, but favorable associations in LIHC, THYM and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HTR1B RNA expression.
This table summarizes HTR1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HTR1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR1B shows lower tumor expression in BLCA, KICH and KIRC and higher tumor expression in HNSC, COAD and LIHC. The HNSC box plot shows higher HTR1B RNA expression in tumor versus normal tissue (log2 FC = +0.301, t-test p < 0.001).
This table shows molecular features associated with HTR1B in patient tissues and cancer cell lines. In patient samples, HTR1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
